A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
Daniel Costin Danila
Research Funding - Genentech
Russell Zelig Szmulewitz
No relevant relationships to disclose
Celestia S. Higano
Research Funding - Genentech
Houston Gilbert
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Robert S. Kahn
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Priya Agarwal
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Kedan Lin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Omar Kabbarah
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Bernard M. Fine
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Ulka N. Vaishampayan
Consultant or Advisory Role - Dendreon; Janssen Oncology; Novartis; Pfizer
Research Funding - Genentech/Roche; Novartis
Other Remuneration - Dendreon (Speakers Bureau); Genentech/Roche; Janssen Biotech (Speakers Bureau); Medivation (Speakers Bureau); Novartis (Speakers Bureau); Pfizer (Educational Presentation Development); Pfizer (Speakers Bureau)